News

Citryll and Lonza have teamed up to develop Citryll’s candidate antibody, called CIT-013, as a therapy for inflammatory diseases, including idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis, the companies announced. CIT-013 is designed to inhibit the formation of web-like structures known as neutrophil extracellular traps (NETs),…

Simultaneous inhibition of two signaling pathways mediated by TGF-beta1 and periostin can halt progression of idiopathic pulmonary fibrosis in mice, a new study reveals.  The study, “The Cross-Talk Between TGF-β and Periostin Can Be Targeted for Pulmonary Fibrosis,” was published in…

Nitric oxide, a gas that induces the relaxation and widening of lung airways, has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The gas will be delivered in pulses through Bellerophon Therapeutics’ patented…

Genetic screening that can identify variants of the mucin-causing MUC5B gene — the key risk factor that predisposes people for idiopathic pulmonary fibrosis (IPF) — may hold the key to the development and administration of targeted therapies that may prevent the disease before it can progress…

Surgery is the most effective option to treat lung cancer in people with less severe idiopathic pulmonary fibrosis (IPF), a Korean study has found. For IPF patients who have a poorer prognosis (more advanced GAP stages), researchers recommend accounting for cancer clinical stage and estimated tolerability…

Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in clinical trials, a new study shows. “Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis” was published in the journal…

The Pulmonary Fibrosis Foundation (PFF) and Three Lakes Partners are joining forces in the fight against pulmonary fibrosis (PF), according to an announcement to mark National Pulmonary Fibrosis Awareness Month in September. Three Lakes Partners will provide funding to PFF to help the foundation reach its goals of…

Processa Pharmaceuticals will explore and further develop the anti-fibrotic, anti-inflammatory compound HT-100 as a potential treatment for rare fibrotic-related diseases in adults, including focal segmental glomerulosclerosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). The company announced that it has acquired the exclusive global rights to develop…

Immune cells can sense the mechanical forces at work in the lungs via a gate called PIEZO1, and deleting this gene in immune cells led to worse lung infections, researchers report. But its loss eased the inflammation associated with lung scarring in a mouse model of pulmonary fibrosis. Their study…

A protein called GDF15, which is secreted by a type of lung cells, is increased in the lungs and blood of people with idiopathic pulmonary fibrosis, a study shows. Supported by this finding, researchers believe that GDF15 may serve as a biomarker to help identify people who have…